SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on October 17, 2017. The report serves as a Regulation FD disclosure, furnishing a press release dated October 17, 2017, to the public. The registrant is incorporated in Delaware with principal executive offices in Louisville, CO.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose a press release and does not contain audited financial statements or quantitative financial data.
Material Changes
The filing does not detail specific material changes to financial performance or operations. It solely references the issuance of a press release (Exhibit 99.1) as the event being reported.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, and specific risk factors are not included in the body of this Form 8-K. The content of the referenced press release is not provided in the source text. The filing explicitly states that the information is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934, and it shall not be deemed an admission as to the materiality of any information.
Key Facts for Investor Verification
- The filing is a Regulation FD disclosure referencing a press release (Exhibit 99.1) not included in the provided text.
- No financial metrics or operational data are present in this specific document.
- Investors must locate and review the attached press release (Exhibit 99.1) to understand the substance of the announcement.
- The information is deemed "furnished" rather than "filed," limiting its legal status under the Exchange Act.